series-a
Stage
2023
Founded
1
Investors
About
Solu Therapeutics develops proprietary Cytoxicity Targeting Chimeras (CyTaCs) that link antibodies to target cells, enabling immune system destruction of cells that lack antibody-binding sites, with an initial focus on blood cancers.
Explore Solu Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.